Low expression of PRMT5 in peripheral blood may serve as a potential independent risk factor in assessments of the risk of stable CAD and AMI

Abstract

BackgroundProtein arginine methyltransferases (PRMTs) can catalyse the methylation of arginine and participate in many important cellular reaction processes. The purpose of this research is to determine whether the expression levels of the PRMT5 gene in peripheral blood can be used as a biomarker for predicting the risk of Acute Myocardial Infarction (AMI).MethodsIn this research, peripheral blood was collected from 91 patients with AMI and 87 patients with stable coronary artery disease (CAD). Real-time fluorescent quantitative PCR was performed to measure the expression levels of the PRMT5 gene at the mRNA level, and a western blot analysis was performed to measure the expression levels of the PRMT5 gene at the protein level.ResultsThe results indicate that at both the RNA and protein levels, the expression levels of the PRMT5 gene in peripheral blood from patients with AMI are significantly lower than those in peripheral blood from patients with stable CAD (Z = − 4.813, P = 0.000). The low expression of the PRMT5 gene is relevant to the Gensini score of the coronary artery (rs = − 0.205, P = 0.015) but is irrelevant to the serum level of blood lipids, level of cardiac troponin (rs = − 0.125, P = 0.413) and time intervals of occurrence (rs = − 0.146, P = 0.211). Patients who have a low PRMT5 expression in the peripheral blood are 5.472 times more likely to suffer from AMI than other patients.ConclusionCompared to stable CAD patients, AMI patients have a lower expression of the PRMT5 gene in their peripheral blood. Patients who have low PRMT5 gene expression in the peripheral blood are more likely to suffer from AMI than those with stable CAD. A low expression of the PRMT5 gene serves as an independent risk factor for the occurrence of AMI.

PRMT5 Prevents Cardiomyocyte Hypertrophy via Symmetric Dimethylating HoxA9 and Repressing HoxA9 Expression

“…The in vivo and in vitro observations that the expression of PRMT5 was decreased in cardiac hypertrophy, imply that repression of PRMT5 might contribute to the development of cardiac hypertrophy. It also helps to explain that human with low expression of PRMT5 in peripheral blood are at high risk of coronary artery disease and acute myocardial infarction (Tan et al, 2019).…”

“…PRMT5 is able to methylate various histones and non-histone substrates, indicating its wide participation in biological process (Ren et al, 2010;Bandyopadhyay et al, 2012;Beltran-Alvarez et al, 2013;Tsai et al, 2013;Girardot et al, 2014;Yang et al, 2015;Webb et al, 2017). People with shrinking expression level of PRMT5 in peripheral blood are prone to developing stable coronary artery disease and acute myocardial infarction (Tan et al, 2019), suggesting that PRMT5 might play a critical role in cardiovascular diseases. Indeed, inhibition of PRMT5 facilitates cardiac hypertrophy through suppression of p300-mediated transcriptional activation of GATA4 (Chen et al, 2014).…”

Transcriptome Signatures Reveal Candidate Key Genes in the Peripheral Blood Mononuclear Cells of Patients With Coronary Artery Disease

“…Genes such as KLKB1 [50], PRMT5 [51], F2R [52] and IL18RAP [53] were liable for progression of CAD. AKAP5 was associated with progression of hypertension [54], but this gene may be identi ed with progression of CAD.…”

The Biomarkers for Acute Myocardial Infarction and Heart Failure

“…Others. e class II phosphatidylinositol 3-phosphate kinase (PIK3C2A) and the protein arginine methyltransferase 5 (PRMT5) expression have been verified to be downregulated in the AMI and are independent risk factors [163,164]. YKL-40 is a novel inflammatory biomarker in cardiovascular disease [165], and the high plasma levels of cys-C are associated with the spectrum of adverse outcomes and risk stratification in cardiovascular diseases [166].…”